Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 2/20 | 0.53 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.53 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.53 |
| ▸ | IL2 | P60568 | 12/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16636685 | 0.95 | IL2 (0.48) | STIM1ORAI1ORAI2IL2KMT2A | |
| SCHEMBL16636678 | 0.90 | IL2 (0.42) | STIM1ORAI1ORAI2IL2SCN9A | |
| SCHEMBL16636766 | 0.89 | STIM1 (0.40) | STIM1ORAI1ORAI2IL2SCN9A | |
| SCHEMBL16637371 | 0.89 | IL2 (0.43) | STIM1ORAI1ORAI2IL2KMT2A | |
| SCHEMBL16636692 | 0.88 | SMN1; SMN2 (0.46) | STIM1ORAI1ORAI2IL2KMT2A | |
| SCHEMBL16636481 | 0.86 | IL2 (0.41) | STIM1ORAI1ORAI2IL2 | |
| SCHEMBL16636946 | 0.84 | IL2 (0.46) | STIM1ORAI1ORAI2IL2KMT2A | |
| SCHEMBL16636428 | 0.84 | IL2 (0.45) | STIM1ORAI1ORAI2IL2KMT2A | |
| SCHEMBL16636688 | 0.84 | IL2 (0.44) | STIM1ORAI1IL2KMT2AMEN1 | |
| SCHEMBL16636612 | 0.83 | IL2 (0.36) | STIM1ORAI1ORAI2IL2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611263-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160229845-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2016-08-11 | — | — | US | disclosed |
| WO-2015054283-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229845-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885ORAI2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.